Radical skeletal metastatic site irradiation in high-risk neuroblastoma: systematic review and proposal for a randomised trial: a report from the SIOPEN Radiotherapy Committee

Abstract

Aim: Neuroblastoma has a variable outcome depending on age, stage, and molecular pathology. Distant metastatic disease is the central feature of high-risk disease. Recommendations for irradiating persistent metastatic deposits with curative intent after systemic therapy vary. It is unclear to what extent this practice may improve local control or survival. This study systematically reviewed the evidence for skeletal metastatic site irradiation and made evidence-based recommendations for clinical practice.

Methods: We systematically reviewed the literature on radical radiotherapy of persistent metastases after chemotherapy. The aim was to determine whether a position could be taken regarding metastatic site irradiation in combined modality treatment protocols aiming for a cure and whether recommendations could be formulated.

Results: The initial search yielded 445 results. After the title and abstract review, 13 full papers were retrieved. Ten papers were found suitable for data extraction. One additional paper was identified. All 11 were graded as Centre for Evidence-Based Medicine Step 4 in quality; there was no high-level evidence. There are suggestions of benefit for skeletal site irradiation in high-risk neuroblastoma; however, there is no certainty, and it was not possible to recommend a particular treatment policy.

Conclusion: We recommend that consideration is given to a randomised evaluation of the benefits of radiotherapy to a limited number of residual post-induction-chemotherapy metastatic sites in good responders. This practice could be incorporated as an amendment to existing trials.

Keywords

Curative intent / high-risk neuroblastoma / skeletal metastases / radical radiotherapy.

References

[1] Matthay KK,Schleiermacher G.Neuroblastoma.Nat Rev Dis Primers2016;2:16078

[2] Cohn SL,London WB.The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.J Clin Oncol2009;27:289-97

[3] Monclair T,Ambros PF.The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report.J Clin Oncol2009;27:298-303 PMCID:PMC2650389

[4] Ambros PF,Brodeur GM.International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee.Br J Cancer2009;100:1471-82 PMCID:PMC2694415

[5] Matthay KK,Ladenstein R.Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force.Br J Cancer2010;102:1319-26

[6] Sung AJ,Sharp SE,Trout AT.Prognostic significance of pretreatment 18F-FDG positron emission tomography/computed tomography in pediatric neuroblastoma.Pediatr Radiol2021;51:1400-5

[7] Berlanga P,Pötschger U.Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience.Eur J Cancer2021;144:1-8

[8] Ladenstein R,Pötschger U.Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials.Eur J Nucl Med Mol Imaging2018;45:292-305 PMCID:PMC5747549

[9] Garaventa A,Valteau-Couanet D.Randomized trial of two induction therapy regimens for high-risk neuroblastoma: HR-NBL1.5 International society of pediatric oncology European neuroblastoma group study.J Clin Oncol2021;39:2552-63

[10] Ladenstein R,Pearson ADJ.Busulfan and melphalan vs. carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.Lancet Oncol2017;18:500-14

[11] Park JR,London WB.Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a randomized clinical trial.JAMA2019;322:746-55 PMCID:PMC6714031

[12] Ladenstein R,Valteau-Couanet D.Investigation of the role of dinutuximab beta-based immunotherapy in the SIOPEN high-risk neuroblastoma 1 Trial (HR-NBL1).Cancers2020;12:309 PMCID:PMC7072500

[13] Yu AL,Ozkaynak MF.Long-term follow-up of a phase III study of ch14.18 (Dinutuximab) + cytokine immunotherapy in children with high-risk neuroblastoma: COG study ANBL0032.Clin Cancer Res2021;27:2179-89 PMCID:PMC8046731

[14] Holmes K,Pearson ADJ.Influence of surgical excision on the survival of patients with stage 4 high-risk neuroblastoma: a report from the HR-NBL1/SIOPEN study.J Clin Oncol2020;38:2902-15

[15] von Allmen D,London WB.Impact of extent of resection on local control and survival in patients from the COG A3973 study with high-risk neuroblastoma.J Clin Oncol2017;35:208-16 PMCID:PMC5455676

[16] Arumugam S,Gains JE,Gaze MN.The evidence for external beam radiotherapy in high-risk neuroblastoma of childhood: a systematic review.Clin Oncol2019;31:182-90

[17] Liu KX,Zhang FF.Prospective evaluation of radiation dose escalation in patients with high-risk neuroblastoma and gross residual disease after surgery: a report from the children’s oncology group ANBL0532 study.J Clin Oncol2020;38:2741-52 PMCID:PMC7430214

[18] Deacon JM,Peckham MJ.The radiobiology of human neuroblastoma.Radiother Oncol1985;3:201-9

[19] Flandin I,Michon J.Impact of TBI on late effects in children treated by megatherapy for Stage IV neuroblastoma. A study of the French Society of Pediatric oncology.Int J Radiat Oncol Biol Phys2006;64:1424-31

[20] Hobbie WL,Carlson C.Late effects in survivors of high-risk neuroblastoma following stem cell transplant with and without total body irradiation.Pediatr Blood Cancer2022;69:e29537

[21] Haas-Kogan DA,Selch M.Impact of radiotherapy for high-risk neuroblastoma: a Children’s Cancer Group study.Int J Radiat Oncol Biol Phys2003;56:28-39

[22] Matthay KK,Lumbroso J.Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma.J Clin Oncol2003;21:2486-91

[23] Schmidt M,Hero B,Berthold F.The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97.Eur J Cancer2008;44:1552-8

[24] Gaze MN,Dieckmann K.Results of a quality assurance review of external beam radiation therapy in the International Society of Paediatric Oncology (Europe) Neuroblastoma Group’s High-risk Neuroblastoma Trial: a SIOPEN study.Int J Radiat Oncol Biol Phys2013;85:170-4

[25] Simon T,Schulte JH.2017 GPOH guidelines for diagnosis and treatment of patients with neuroblastic tumors.Klin Padiatr2017;229:147-67

[26] Moher D,Clarke M.Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.Syst Rev2015;4:1

[27] Brodeur GM,Berthold F.Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.J Clin Oncol1993;11:1466-77

[28] Centre for evidence-based medicine: critical appraisal tools. Available from: https://www.cebm.ox.ac.uk/resources/ebm-tools/critical-appraisal-tools [Last accessed on 10 Feb 2023]

[29] Centre for evidence-based medicine: finding the evidence: a how-to guide. Available from: https://www.cebm.ox.ac.uk/resources/ebm-tools/finding-the-evidence-tutorial [Last accessed on 10 Feb 2023]

[30] Casey DL,Kushner BH.Radiation therapy to sites of metastatic disease as part of consolidation in high-risk neuroblastoma: can long-term control be achieved?.Int J Radiat Oncol Biol Phys2018;100:1204-9

[31] Polishchuk AL,Hill-Kayser C.Likelihood of bone recurrence in prior sites of metastasis in patients with high-risk neuroblastoma.Int J Radiat Oncol Biol Phys2014;89:839-45

[32] Jazmati D,Hero B.Long-term follow-up of children with neuroblastoma receiving radiotherapy to metastatic lesions within the German Neuroblastoma Trials NB97 and NB 2004.Strahlenther Onkol2021;197:683-9 PMCID:PMC8292260

[33] Kushner BH,Barker CA.Hyperfractionated low-dose (21 Gy) radiotherapy for cranial skeletal metastases in patients with high-risk neuroblastoma.Int J Radiat Oncol Biol Phys2009;75:1181-6 PMCID:PMC5587173

[34] Bagley AF,Philip NV.Efficacy of proton therapy in children with high-risk and locally recurrent neuroblastoma.Pediatr Blood Cancer2019;66:e27786 PMCID:PMC6588416

[35] Li R,DuBois S.Patterns of relapse in high-risk neuroblastoma patients treated with and without total body irradiation.Int J Radiat Oncol Biol Phys2017;97:270-7

[36] Mazloom A,Nuchtern J.Radiation therapy to the primary and postinduction chemotherapy MIBG-avid sites in high-risk neuroblastoma.Int J Radiat Oncol Biol Phys2014;90:858-62 PMCID:PMC5107988

[37] Kandula S,Nanda R.Outcomes after radiation therapy to metastatic sites in patients with stage 4 neuroblastoma.J Pediatr Hematol Oncol2015;37:175-80 PMCID:PMC4869887

[38] Bradfield SM,Hawkins DS,Park JR.Fractionated low-dose radiotherapy after myeloablative stem cell transplantation for local control in patients with high-risk neuroblastoma.Cancer2004;100:1268-75

[39] Sibley GS,Goldman S.Patterns of failure following total body irradiation and bone marrow transplantation with or without a radiotherapy boost for advanced neuroblastoma.Int J Radiat Oncol Biol Phys1995;32:1127-35

[40] Sangthawan D,Randall ME,Goebel S.Relapse in the skull after myeloablative therapy for high-risk neuroblastoma.Pediatr Hematol Oncol2003;20:23-30

[41] Huijskens SC,Gaze MN.Radical radiotherapy for paediatric solid tumour metastases: An overview of current European protocols and outcomes of a SIOPE multicenter survey.Eur J Cancer2021;145:121-31

[42] Kraal KC,van Eck-Smit BL.Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients.Eur J Cancer2017;76:188-96

[43] Foster JH,Hall DC.Activity of crizotinib in patients with ALK-aberrant relapsed/refractory neuroblastoma: a children’s oncology group study (ADVL0912).Clin Cancer Res2021;27:3543-8 PMCID:PMC8254744

[44] Chung C,Lucas J.Neuroblastoma.Pediatr Blood Cancer2021;68:e28473

[45] Zhao Q,Zhang Y.Role and toxicity of radiation therapy in neuroblastoma patients: A literature review.Crit Rev Oncol Hematol2020;149:102924